Poor survival in ovarian cancer patients is correlated with high RUNX1 expression levels, and depletion of RUNX1 in ovarian cancer cells elevates cisplatin sensitivity [16,66,67]. This evidence concerns the gene RUNX1 and ovarian cancer.